| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $7.0M | +71.1% | +117.7% |
| SG&A Expense | $3.7M | +1.7% | +12.1% |
| Operating Income | -$10.7M | -38.6% | -64.4% |
| Pre-tax Income | -$10.3M | -40.2% | -77.1% |
| Income Tax | $0 | — | — |
| Net Income | -$8.7M | -43.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $98.5M | +280.0% | +137.0% |
| Current Assets | $99.5M | +277.1% | +131.5% |
| Total Assets | $99.5M | +276.2% | +130.5% |
| Current Liabilities | $10.2M | +91.9% | +58.2% |
| Total Liabilities | $29.0M | +20.4% | +14.7% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$16.0M | — | — |
| Financing Cash Flow | $77.8M | — | — |
| -81.9% |
| $70.5M |
| +2454.1% |
| +370.0% |